• Publications
  • Influence
Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study
Ospemifene was shown to be effective and well tolerated for the treatment of the symptoms of vaginal dryness and dyspareunia associated with vulvovaginal atrophy over and above the use of provided lubricants.
Diagnosis and treatment of atrophic vaginitis.
The earliest symptoms are decreased vaginal lubrication, followed by other vaginal and urinary symptoms that may be exacerbated by superimposed infection, and treatment usually depends on estrogen replacement.
Prevalence of sexual dysfunction in women: results of a survey study of 329 women in an outpatient gynecological clinic.
Age and relationship status were significant predictors of sexual satisfaction, with older women and singles reporting a higher incidence of sexual problems, and educational level, religious affiliation, and employment status were not predictive of sexual dysfunction in the present study.
Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy
In this study, once-daily oral ospemifene 60 mg was effective for the treatment of vulvar and vaginal atrophy in postmenopausal women with dyspareunia.